yahoo.brand.edgar-online.com/...efault.aspx%253fcik%253d884731
ARIAD PHARMACEUTICALS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
§
In thousands, except per share data Three Months Ended March 31,
§2014 2013
§(Unaudited) (Unaudited)
Total revenue $ 11,782 $ 6,464
Operating expenses:
Cost of product revenue 1,288 269
Research and development 28,554 41,263
General and administrative 31,591 29,481
Total operating expenses 61,433 71,013
Other income (expense), net (52 ) (62 )
Provision for income taxes 119 59
Net loss
§ $ (49,822 ) $ (64,670 )
Net loss per common share:
-- basic and diluted $ (0.27 ) $ (0.36 )
Weighted average number of shares of common stock outstanding:
-- basic and diluted 186,252 178,541
§